154 related articles for article (PubMed ID: 16286895)
1. Risk stratification in cardiac amyloidosis: novel approaches.
Kristen AV; Meyer FJ; Perz JB; Schonland SO; Hundemer M; Hegenbart U; Singer R; Schnabel PA; Sack FU; Goldschmidt H; Katus HA; Dengler TJ
Transplantation; 2005 Sep; 80(1 Suppl):S151-5. PubMed ID: 16286895
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
3. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
[TBL] [Abstract][Full Text] [Related]
4. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
5. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
[TBL] [Abstract][Full Text] [Related]
7. Cardiac amyloidosis: a practical approach to diagnosis and management.
Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR
Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778
[TBL] [Abstract][Full Text] [Related]
8. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis.
Kreusser MM; Volz MJ; Knop B; Ehlermann P; Schmack B; Ruhparwar A; Hegenbart U; Schönland SO; Katus HA; Raake PW
Clin Res Cardiol; 2020 Jun; 109(6):700-713. PubMed ID: 31630214
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
10. Cardiac amyloidosis - experience in a tertiary cardiac referral centre.
Chau EM; Chow WH; Wang E; Kwong YL
Int J Cardiol; 2008 Feb; 124(2):264-6. PubMed ID: 17383027
[TBL] [Abstract][Full Text] [Related]
11. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
13. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis.
Hamer JP; Janssen S; van Rijswijk MH; Lie KI
Eur Heart J; 1992 May; 13(5):623-7. PubMed ID: 1618203
[TBL] [Abstract][Full Text] [Related]
14. Current trends in diagnosis and management of cardiac amyloidosis.
Esplin BL; Gertz MA
Curr Probl Cardiol; 2013 Feb; 38(2):53-96. PubMed ID: 23337445
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
16. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.
Bhutani D; Pan S; Latif F; Goldsmith RL; Saith SE; Mapara MY; Chakraborty R; Lentzsch S; Maurer MS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):545-548. PubMed ID: 34024744
[TBL] [Abstract][Full Text] [Related]
17. Cardiac manifestations of amyloid disease.
Rivera RJ; Vicenty S
Bol Asoc Med P R; 2008; 100(4):60-70. PubMed ID: 19400531
[TBL] [Abstract][Full Text] [Related]
18. Cardiac amyloidosis.
Maredia N; Ray SG
Clin Med (Lond); 2005; 5(5):504-9. PubMed ID: 16268336
[TBL] [Abstract][Full Text] [Related]
19. [Cardiac amyloidosis].
Hoyer C; Angermann CE; Knop S; Ertl G; Störk S
Med Klin (Munich); 2008 Mar; 103(3):153-60. PubMed ID: 18344065
[TBL] [Abstract][Full Text] [Related]
20. Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study.
Cicco S; Solimando AG; Buono R; Susca N; Inglese G; Melaccio A; Prete M; Ria R; Racanelli V; Vacca A
Life (Basel); 2020 Oct; 10(10):. PubMed ID: 33081052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
